These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 31642863)

  • 21. Stimulant use under a prison treatment protocol for attention-deficit/hyperactivity disorder.
    Appelbaum KL
    J Correct Health Care; 2011 Jul; 17(3):218-25. PubMed ID: 21474530
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Attention-Deficit Hyperactivity Disorder.
    DuPont RL
    Essent Psychopharmacol; 2005; 6(5):iv. PubMed ID: 16222908
    [No Abstract]   [Full Text] [Related]  

  • 23. Attention-deficit/hyperactivity disorder and substance abuse.
    Harstad E; Levy S;
    Pediatrics; 2014 Jul; 134(1):e293-301. PubMed ID: 24982106
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Does the medicating ADHD increase or decrease the risk for later substance abuse?
    Wilens TE
    Braz J Psychiatry; 2003 Sep; 25(3):127-8. PubMed ID: 12975683
    [No Abstract]   [Full Text] [Related]  

  • 25. Expert Opinion and Recommendations for the Management of Attention-Deficit/Hyperactivity Disorder in Correctional Facilities.
    Scott DA; Gignac M; Kronfli RN; Ocana A; Lorberg GW
    J Correct Health Care; 2016 Jan; 22(1):46-61. PubMed ID: 26672119
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Stimulant misuse in college for "pseudo-attention deficit disorder" during schizophrenia prodrome.
    Freudenreich O; Cather C; Holt D
    Am J Psychiatry; 2006 Nov; 163(11):2019. PubMed ID: 17074965
    [No Abstract]   [Full Text] [Related]  

  • 27. Methylphenidate-induced psychosis in adult attention-deficit/hyperactivity disorder: report of 3 new cases and review of the literature.
    Kraemer M; Uekermann J; Wiltfang J; Kis B
    Clin Neuropharmacol; 2010 Jul; 33(4):204-6. PubMed ID: 20571380
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Necessity for research directed at stimulant type and treatment-onset age to access the impact of medication on drug abuse vulnerability in teenagers with ADHD.
    Kantak KM; Dwoskin LP
    Pharmacol Biochem Behav; 2016 Jun; 145():24-6. PubMed ID: 27012495
    [No Abstract]   [Full Text] [Related]  

  • 29. Do stimulants prevent substance use and misuse among youth with attention-deficit/hyperactivity disorder? The answer is still maybe.
    Goldstein BI
    J Am Acad Child Adolesc Psychiatry; 2013 Mar; 52(3):225-7. PubMed ID: 23452678
    [No Abstract]   [Full Text] [Related]  

  • 30. A reply to critics of using stimulants to treat attention deficit hyperactivity disorder.
    Pliszka SR
    Tex Med; 1991 Apr; 87(4):84-7. PubMed ID: 1674631
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Abuse liability of medications used to treat attention-deficit/hyperactivity disorder (ADHD).
    Kollins SH
    Am J Addict; 2007; 16 Suppl 1():35-42; quiz 43-4. PubMed ID: 17453605
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacotherapy for attention-deficit/hyperactivity disorder (ADHD) decreases the risk for substance abuse: findings from a longitudinal follow-up of youths with and without ADHD.
    Biederman J
    J Clin Psychiatry; 2003; 64 Suppl 11():3-8. PubMed ID: 14529323
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacotherapy of attention-deficit/hyperactivity disorder reduces risk for substance use disorder.
    Biederman J; Wilens T; Mick E; Spencer T; Faraone SV
    Pediatrics; 1999 Aug; 104(2):e20. PubMed ID: 10429138
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Stimulant medications: how to minimize their reinforcing effects?
    Volkow ND
    Am J Psychiatry; 2006 Mar; 163(3):359-61. PubMed ID: 16513852
    [No Abstract]   [Full Text] [Related]  

  • 35. ADHD treatment and the risk of substance abuse.
    Sircy RA; Stojanoski A
    Nurse Pract; 2008 Apr; 33(4):33-6. PubMed ID: 18388552
    [No Abstract]   [Full Text] [Related]  

  • 36. Stimulant treatment for attention-deficit hyperactivity disorder and risk of developing substance use disorder.
    Groenman AP; Oosterlaan J; Rommelse NN; Franke B; Greven CU; Hoekstra PJ; Hartman CA; Luman M; Roeyers H; Oades RD; Sergeant JA; Buitelaar JK; Faraone SV
    Br J Psychiatry; 2013 Aug; 203(2):112-9. PubMed ID: 23846996
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FDA ponders cardiovascular risks of ADHD drugs.
    Young D
    Am J Health Syst Pharm; 2006 Mar; 63(6):492-4. PubMed ID: 16522874
    [No Abstract]   [Full Text] [Related]  

  • 38. Attention deficit hyperactivity disorder and substance use disorders: Is there a causal link?
    Lynskey MT; Hall W
    Addiction; 2001 Jun; 96(6):815-22. PubMed ID: 11399213
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adult ADHD: diversion and misuse of medications.
    Spencer TJ
    CNS Spectr; 2008 Oct; 13(10 Suppl 15):9-13. PubMed ID: 18955949
    [No Abstract]   [Full Text] [Related]  

  • 40. Attention-deficit/hyperactivity disorder: the road traveled and the road ahead.
    Jun A
    Am J Health Syst Pharm; 2009 Nov; 66(22):2003. PubMed ID: 19890082
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.